Instalación de carillas de disilicato de litio

El disilicato de litio es un nuevo material compuesto de cerámica y vidrio que se utiliza en la fabricación de prótesis dentales de una sola pieza, como puentes con tres piezas, puentes premolares e incluso posteriores. Los avances tecnológicos y la constante búsqueda de combinación de elementos para conseguir resultados de más calidad, nos permiten hoy en día trabajar con materiales seguros y rozar la perfección en nuestro trabajo. Cada vez son más los pacientes que nos preguntan sobre los materiales dentales que utilizamos para devolverles la sonrisa. Uno que despierta gran interés es el disilicato de Litio y cómo es su aplicación en estética dental. Buscamos siempre sonrisas deslumbrantes pero naturales y al mismo tiempo tratamos de resolverlos los casos complejos de estética dental. La formación nuestra y la tecnología más avanzada que utilizamos en nuestras clínicas universitarias garantizan nuestro trabajo. Y esa garantía que podemos ofrecer es la que nos mueve para facilitar la información que estás buscando sobre este nuevo material utilizado en estética dental como es el disilicato de Litio. El presente caso clínico enmarca la confección e instalación de las carillas de disilicato de litio, el cual lo iremos explicando paso a paso por ser este un tema novedoso e importante en el mundo de la odontología brindando mucha estética para que los pacientes puedan volver a sonreír

Ice-fuelled food webs in the Polar Oceans

The Arctic Ocean is undergoing substantial warming and sea ice loss which are likely to cause changes in primary production, export fluxes and productivity of the Arctic marine ecosystems. Yet, we lack sufficient information about the ecosystem productivity, organic carbon cycling and cryo-pelago-benthic coupling processes in the Arctic Ocean. Particularly such information is scarce for deep Arctic basins and the spring to summer transition time. Our aim was to provide carbon budget estimations under different regimes and bloom development stages in the region north of Svalbard. We conducted ecological and biogeochemical early spring process studies in sea ice covered areas, from the shelf to the basins of the European Arctic margin and on the Yermak Plateau during the TRANSSIZ cruise PS 92 on the ice breaker R/V Polarstern in May/June 2015. We identified the potential characteristics of carbon production of primary producers in the sea ice and water column, and secondary production of zooplankton and benthos. We looked into the organic carbon production fate and export, including respiration and burial, as well as identified similarities and differences in ecosystem functioning along topography- , sea ice- and water mass-related gradients. This scientific initiative was undertaken by Arctic in Rapid Transition (ART) International Arctic Science Committee (IASC) network

Non-neutralizing Antibodies May Contribute to Suppression of SIVmac239 Viremia in Indian Rhesus Macaques

The antiviral properties of broadly neutralizing antibodies against HIV are well-documented but no vaccine is currently able to elicit protective titers of these responses in primates. While current vaccine modalities can readily induce non-neutralizing antibodies against simian immunodeficiency virus (SIV) and HIV, the ability of these responses to restrict lentivirus transmission and replication remains controversial. Here, we investigated the antiviral properties of non-neutralizing antibodies in a group of Indian rhesus macaques (RMs) that were vaccinated with vif, rev, tat, nef, and env, as part of a previous study conducted by our group. These animals manifested rapid and durable control of viral replication to below detection limits shortly after SIVmac239 infection. Although these animals had no serological neutralizing activity against SIVmac239 prior to infection, their pre-challenge titers of Env-binding antibodies correlated with control of viral replication. To assess the contribution of anti-Env humoral immune responses to virologic control in two of these animals, we transiently depleted their circulating antibodies via extracorporeal plasma immunoadsorption and inhibition of IgG recycling through antibody-mediated blockade of the neonatal Fc receptor. These procedures reduced Ig serum concentrations by up to 80% and temporarily induced SIVmac239 replication in these animals. Next, we transferred purified total Ig from the rapid controllers into six vaccinated RMs one day before intrarectal challenge with SIVmac239. Although recipients of the hyperimmune anti-SIV Ig fraction were not protected from infection, their peak and chronic phase viral loads were significantly lower than those in concurrent unvaccinated control animals. Together, our results suggest that non-neutralizing Abs may play a role in the suppression of SIVmac239 viremia

Informe del Seminario sobre Políticas de Ajuste e Integración en Centroamérica

Expression levels of metastasis-associated genes in the Tumor Metastasis array. Values displayed include mean ΔCT, along with SEM, confidence intervals, and p values derived from t-tests for the corresponding comparisons. Samples with insufficient material are indicated as not determined (N/D), and p values are not provided for these comparisons. (XLSX 29 kb

Biomolecular Triconjugates Formed between Gold, Protamine, and Nucleic Acid: Comparative Characterization on the Nanoscale

DNA and RNA micro- and nanoparticles are increasingly being used for gene and siRNA drug delivery and a variety of other applications in bionanotechnology. On the nanoscale, these entities represent unique challenges from a physicochemical characterization perspective. Here, nucleic acid conjugates with protamine and gold nanoparticles (GNP) were characterized comparatively in the nanorange of concentration by UV/Vis NanoDrop spectroscopy, fluorimetry, and gel electrophoresis. Given the intense interest in splice-site switching oligomers (SSOs), we utilized a human tumor cell culture system (HeLa pLuc-705), in which SSO-directed splicing repair upregulates luciferase expression, in order to investigate bioactivity of the bionanoconjugates. Process parameters important for bioactivity were investigated, and the bimolecular nanoconjugates were confirmed by shifts in the dynamic laser light scatter (DLLS), UV/Vis spectrum, gel electrophoresis, or sedimentation pattern. The data presented herein may be useful in the future development of pharmaceutical and biotechnology formulations, processes, and analyses concerning protein, DNA, or RNA bionanoconjugates

Standardising personalised diabetes care across European health settings:A person-centred outcome set agreed in a multinational Delphi study

ObjectiveStandardised person-reported outcomes (PRO) data can contextualise clinical outcomes enabling precision diabetes monitoring and care. Comprehensive outcome sets can guide this process, but their implementation in routine diabetes care has remained challenging and unsuccessful at international level. We aimed to address this by developing a person-centred outcome set for Type 1 and Type 2 diabetes, using a methodology with prospects for increased implementability and sustainability in international health settings.MethodsWe used a three-round questionnaire-based Delphi study to reach consensus on the outcome set. We invited key stakeholders from 19 countries via purposive snowball sampling, namely people with diabetes (N = 94), healthcare professionals (N = 65), industry (N = 22) and health authorities (N = 3), to vote on the relevance and measurement frequency of 64 previously identified clinical and person-reported outcomes. Subsequent consensus meetings concluded the study.ResultsThe list of preliminary outcomes was shortlisted via the consensus process to 46 outcomes (27 clinical outcomes and 19 PROs). Two main collection times were recommended: (1) linked to a medical visit (e.g. diabetes-specific well-being, symptoms and psychological health) and (2) annually (e.g. clinical data, general well-being and diabetes self management-related outcomes).ConclusionsPROs are often considered in a non-standardised way in routine diabetes care. We propose a person-centred outcome set for diabetes, specifically considering psychosocial and behavioural aspects, which was agreed by four international key stakeholder groups. It guides standardised collection of meaningful outcomes at scale, supporting individual and population level healthcare decision making. It will be implemented and tested in Europe as part of the H2O project

Standardising personalised diabetes care across European health settings:A person-centred outcome set agreed in a multinational Delphi study

ObjectiveStandardised person-reported outcomes (PRO) data can contextualise clinical outcomes enabling precision diabetes monitoring and care. Comprehensive outcome sets can guide this process, but their implementation in routine diabetes care has remained challenging and unsuccessful at international level. We aimed to address this by developing a person-centred outcome set for Type 1 and Type 2 diabetes, using a methodology with prospects for increased implementability and sustainability in international health settings.MethodsWe used a three-round questionnaire-based Delphi study to reach consensus on the outcome set. We invited key stakeholders from 19 countries via purposive snowball sampling, namely people with diabetes (N = 94), healthcare professionals (N = 65), industry (N = 22) and health authorities (N = 3), to vote on the relevance and measurement frequency of 64 previously identified clinical and person-reported outcomes. Subsequent consensus meetings concluded the study.ResultsThe list of preliminary outcomes was shortlisted via the consensus process to 46 outcomes (27 clinical outcomes and 19 PROs). Two main collection times were recommended: (1) linked to a medical visit (e.g. diabetes-specific well-being, symptoms and psychological health) and (2) annually (e.g. clinical data, general well-being and diabetes self management-related outcomes).ConclusionsPROs are often considered in a non-standardised way in routine diabetes care. We propose a person-centred outcome set for diabetes, specifically considering psychosocial and behavioural aspects, which was agreed by four international key stakeholder groups. It guides standardised collection of meaningful outcomes at scale, supporting individual and population level healthcare decision making. It will be implemented and tested in Europe as part of the H2O project

Mutation of RNA Pol III Subunit rpc2/polr3b Leads to Deficiency of Subunit Rpc11 and Disrupts Zebrafish Digestive Development

The role of RNA polymerase III (Pol III) in developing vertebrates has not been examined. Here, we identify a causative mutation of the second largest Pol III subunit, polr3b, that disrupts digestive organ development in zebrafish slim jim (slj) mutants. The slj mutation is a splice-site substitution that causes deletion of a conserved tract of 41 amino acids in the Polr3b protein. Structural considerations predict that the slj Pol3rb deletion might impair its interaction with Polr3k, the ortholog of an essential yeast Pol III subunit, Rpc11, which promotes RNA cleavage and Pol III recycling. We engineered Schizosaccharomyces pombe to carry an Rpc2 deletion comparable to the slj mutation and found that the Pol III recovered from this rpc2-Δ yeast had markedly reduced levels of Rpc11p. Remarkably, overexpression of cDNA encoding the zebrafish rpc11 ortholog, polr3k, rescued the exocrine defects in slj mutants, indicating that the slj phenotype is due to deficiency of Rpc11. These data show that functional interactions between Pol III subunits have been conserved during eukaryotic evolution and support the utility of zebrafish as a model vertebrate for analysis of Pol III function